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A B S T R A C T
Background: Venom immunotherapy is effective in preventing systemic allergic reactions (SARs), but the
diagnosis of venom allergy is problematic.
Objective: To compare the performance of component-resolved diagnosis and conventional tests in pa-
tients referred for venom immunotherapy.
Methods: We measured serum-specific immunoglobulin E to yellowjacket and honeybee venoms (Ves v 1
and Ves v 5 and Api m 1), cross-reactive carbohydrate determinants, serum basal tryptase (ImmunoCAP,
ThermoFisher Scientific, Uppsala, Sweden), and skin prick test reactions in 84 patients referred to receive
venom immunotherapy. History of SAR and its severity were evaluated.
Results: Of the 78 patients with suspected yellowjacket venom (YJV) allergy, a history of SAR was con-
firmed in 47 (60%) and 31 (40%) had a non-SAR reaction. The most accurate tests to confirm venom allergy
after a SAR were serum-specific immunoglobulin E to yellowjacket whole-venom extract spiked with Ves v
5 (area under the curve 0.87, 95% confidence interval 0.77–0.97, P < .001) and Ves v 5 (area under the curve
0.86, 95% confidence interval 0.76–0.96, P < .001). Sensitization to Ves v 1 was infrequent and its area under
the curve was low (0.62, 95% confidence interval 0.47–0.76, P = .106). Sensitivity of the YJV skin prick test
was 86%, but its specificity was low at 54%. Double sensitization to yellowjacket and honeybee occurred fre-
quently in skin prick tests. Of the patients without a SAR, 26% showed a positive reaction to YJV in any serum
test and 46% showed a positive reaction in skin tests.
Conclusion: Specific immunoglobulin E to the YJV spiked with Ves v 5 confirmed the allergy after a SAR. A
history of SAR should be confirmed before testing, because venom sensitization is frequent in other types
of reactions.
© 2017 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Introduction
Hymenoptera venom allergy is a potentially life-threatening con-
dition after an insect sting. Hymenoptera stings cause anaphylaxis
more frequently in adults (3%) than in children (0.34%) and account
for one fourth of fatalities caused by anaphylaxis.1 Systemic mas-
tocytosis increases the risk for severe anaphylaxis to Hymenoptera
stings.2–4 The risk of a systemic allergic reaction (SAR) to Hyme-
noptera re-stings is 25% to 75% in adults with a previous SAR. The
risk depends on the severity of previous reactions and other known
high-risk factors such as age and medication.5 Children have lower
risk of a SAR at re-stings and their SARs are mild in 60%.6,7
Venom immunotherapy (VIT) with extracted Hymenoptera
venoms is effective in preventing a SAR to insect stings: fewer than
3% of patients treated with vespid VIT have a subsequent SAR. VIT
can prevent fatal reactions, and it effectively improves quality of life.8
The prerequisite for efficacious VIT is a history of a SAR to an insect
sting and immunoglobulin E (IgE) sensitization to the culprit venom.
The assessment of IgE sensitization can be problematic because
honeybee (Apis mellifera; Api m) and yellowjacket (Vespula vul-
garis; Ves v) venom extracts are complex mixtures of proteins
including venom-specific and cross-reactive components. The major
allergens are hyaluronidases (Api m 2, Ves v 2), phospholipase A2
(Api m 1), phospholipase A1 (Ves v 1), acidic phosphatase (Api m
3), icarapin (Api m 10), and antigen 5 (Ves v 5).6,9
Double sensitization to yellowjacket and honeybee venoms as
determined by skin prick tests and serum-specific IgE tests is
common; up to 50% of patients show a positive reaction to the 2
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venoms. The major cross-reactive components in honeybee and
yellowjacket venoms are hyaluronidases with 50% sequence iden-
tity. Furthermore, cross-reactive carbohydrate determinants (CCDs)
cause double-positive test results.6 In addition to clinically insig-
nificant positive test results, venom extracts might lack important
low-abundance allergens, resulting in false-negative test results.
The distinction between cross-reactivity and true sensitization
is important for the choice of VIT, because treating patients who
are not sensitized to the allergens in the VIT extract can cause de
novo sensitizations, missing protection, and unnecessary costs.9,10
The current diagnostic framework in Hymenoptera venom
allergy includes skin prick tests, stepwise intradermal testing, and
serum-specific IgE to whole-venom extracts and to venom-
specific allergen components.11 The conventional yellowjacket
venom (YJV) extract in ImmunoCAP alone has shown lower sensi-
tivity than the combination of Ves v 5 and Ves v 1. Therefore, it is
spiked (sYJV) with Ves v 5. When using the sYJV instead of the
conventional YJV, the sensitivity increased from 83% to nearly
97%.12 In the US guidelines, venom testing usually requires intra-
dermal testing for optimal sensitivity, and prick tests are optional.5
In addition, basophil activation tests and in-house immunoblot
tests have been used. Component-resolved diagnostics has im-
proved for the diagnosis of Hymenoptera venom allergy. Measuring
specific IgE to allergen components instead of venom extracts
helps to distinguish true sensitization from cross-reactivity. We
studied the performance of diagnostic tests, including skin prick
tests, serum-specific IgE, in-house immunoblot, and serum base-
line tryptase, in patients with a strong suspicion of venom allergy
referred for VIT.
Methods
Study Population and Classification of Allergic Symptoms
The study population of this case-control study consisted of chil-
dren and adults referred for VIT for suspected Hymenoptera venom
allergy. The cases had a SAR to a Hymenoptera sting and the con-
trols had a large local reaction or other type of reaction. The study
took place at a single center, a tertiary care hospital. We recruited
30 patients retrospectively from March 2010 through December 2013
and 54 prospectively in 2014. An allergist examined the patients
and recorded the history of hymenoptera stings: date, symptoms,
signs, emergency visits, and medication. The stinging insect was
identified by the patient or by the caregiver. We defined a SAR as
a sudden-onset reaction with rapid progression of signs and symp-
toms involving at least 2 organs including dermatologic (generalized
urticaria or erythema, angioedema, or generalized pruritus and skin
rash), cardiovascular (hypotension or clinical diagnosis of uncom-
pensated shock), and respiratory (wheeze, stridor, upper airway
swelling, or respiratory distress) symptoms. Generalized urticaria
without any other symptoms was defined as a SAR in adults. Minor
criteria included milder dermatologic, cardiovascular, respiratory,
and gastrointestinal signs and symptoms. The definition was based
on the Brighton Collaboration Anaphylaxis Working Group sugges-
tion described in detail by Ruggeberg et al.13 Severity of the reaction
was graded as suggested by Mueller,14 referenced in Bilo et al6: grade
I was generalized urticaria, itching, malaise, and anxiety; grade II
was any grade I reaction plus at least 2 of the following: angio-
edema, chest constriction, nausea, vomiting, diarrhea, abdominal
pain, and dizziness; grade III was any grade II reaction plus at least
2 of the following: dyspnea, wheezing, stridor, dysarthria, hoarse-
ness, weakness, confusion, and feeling of impending disaster; and
grade IV was any grade III reaction plus at least 2 of the following:
decrease in blood pressure, collapse, loss of consciousness, incon-
tinence, and cyanosis. A large local reaction was defined as a swelling
exceeding 10 cm lasting at least 24 hours.
Allergy Tests
Skin prick tests were carried out on the patient’s inner forearm
with a disposable single-use lancet. The yellowjacket and honey-
bee venoms were tested at 100 and 300 μg/mL, respectively (ALK-
Abello, Hørsholm, Denmark). Histamine chloride (10 mg/mL) was
the positive control, and the solvent was the negative control. A re-
action wheal of at least 3 mm was considered positive. We measured
serum basal tryptase and specific IgE to sYJV (i3), honeybee venom
(i1), CCD (o214), Ves v 1 (i211), Ves v 5 (i209), and Api m 1 (i208;
ImmunoCAP, ThermoFisher Scientific, Uppsala, Sweden). We defined
sensitization conventionally as a specific IgE level of at least 0.35 kU/
L. Since 2012, the conventional YJV ImmunoCAP has been spiked
with Ves v 5.12 All samples taken before September 2012 were re-
analyzed using the sYJV ImmunoCAP. In addition, an in-house
Immunospot method15 was used to evaluate serum IgE antibodies
to YJV and honeybee venom. For the test, 300 μg/mL of Vespula
species (ALK-Abelló), 20,000 μg/mL of Vespula species European mix
(Allergon, Ängelholm, Sweden), and 300 μg/mL of A mellifera (ALK-
Abelló) venoms were used. A nonatopic serum served as a control.
Statistical Methods and Ethics
The main outcome measure was the accuracy of any diagnos-
tic test in confirming venom allergy in a patient with SAR. We
applied receiver-operating characteristics and area under the curve
(AUC) to evaluate the performance of the tests in SAR and non-
SAR categories. We calculated sensitivity, specificity, and likelihood
ratios with 95% confidence interval (CI). We calculated positive and
negative predictive values for specific IgE concentrations. Spear-
man rank correlation served to correlate severity with the specific
IgE concentrations. Mann-Whitney U test was used to compare non-
normally distributed data, and Pearson χ2 or Fisher exact test was
used for categorical data. SPSS 21 (SPSS, Inc, Chicago, Illinois) was
used for the analyses. The local ethics committee approved the study
protocol, according to which the patient (or 1 parent of the child)
signed a written informed consent. The study followed the prin-
ciples of the Declaration of Helsinki.
Results
Of the 84 patients, 78 were referred for VIT after a yellowjacket
sting, 5 after a honeybee sting, and 1 after a sting by an unknown
insect. The median age was 44 years (range 1–75); 24 (28%) were
children or adolescents. All children with urticaria (13 of the 23)
had other symptoms (dyspnea, vomiting, or angioedema). The per-
formance of the allergy tests was evaluated for yellowjacket allergy
in the 78 individuals. Of these patients, 47 (60%) had experienced
a SAR and 31 (40%) had a non-SAR. The study included only 4 pa-
tients with a SAR triggered by honeybee venom. The demographic
data and test results of the 78 subjects with a yellowjacket sting
are presented in Table 1.
Patients with a SAR to yellowjacket sting were more frequently
sensitized to sYJV (P < .001) and Ves v 5 (P < .001), and they had
higher specific IgE to sYJV (P < .001) and Ves v 5 (P < .001) than those
with a non-SAR. The best accuracy was obtained using specific IgE
to sYJV (AUC 0.87, 95% CI 0.77–0.97, P < .001) and to Ves v 5 (AUC
0.86, 95% CI 0.76–0.96, P < .001). The AUC of specific IgE to Ves v 1
was lower (0.62, 95% CI 0.47–0.76, P = .106; Fig 1).
Specific IgE to sYJV had the best likelihood ratio (3.2), with 89%
sensitivity and 74% specificity. Sensitivity of the skin prick test was
86%, but its specificity was lower at 54%. Accordingly, of the pa-
tients with a non-SAR to yellowjacket, 46% were sensitized to skin
prick tests and 26% were sensitized to the serum sYJV test. Sensi-
tivity of the immunoblot was the lowest at 62%. The performances
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of the diagnostic tests are presented in Table 2. Fig 2 shows the sen-
sitization patterns of the patients with a SAR to yellowjacket sting.
Of the 15 serum samples that were negative to the convention-
al YJV-specific IgE, 7 (47%) were positive in the sYJV test spiked with
Ves v 5.
Double sensitization to yellowjacket and honeybee whole-
venom extracts was more common to skin prick tests than to serum
tests. Of all patients with suspected YJV or honeybee venom allergy,
24 of 61 (39%) were doubly sensitized to titrated skin prick tests,
and 13 of 82 (16%) were doubly sensitized to serum tests. Sensi-
tization to the CCD did not explain double sensitization in serum
tests. Of the double-positive serum tests, 10 (77%) were positive only
to Ves v 5, 3 (23%) were positive to Ves v 5 and Api m 1, and 8 (62%)
were positive to CCD.
Specific IgE to sYJV correlated strongly to Ves v 5 (r = 0.98,
P < .001), whereas the correlation to Ves v 1 was weaker (r = 0.60,
P < .001). The correlation between Ves v 1 and Ves v 5 was 0.56
(P < .001). The YJV immunoblot correlated weakly to sYJV (r = 0.38,
P < .001) and to Ves v 5 (r = 0.37, P < .001) but did not correlate to
Ves v 1. Specific IgE to honeybee venom correlated strongly with
Api m 1 (r = 0.98, P < .001). Honeybee venom immunoblot showed
a moderate correlation to honeybee venom IgE (r = 0.58, P < .001)
and to Api m 1 (r = 0.56, P < .001). None of the tests correlated with
serum basal tryptase.
Severity of the reaction (grades I–IV) showed a moderate to weak
correlation to sYJV (r = 0.40, P < .001) and to Ves v 5 (r = 0.38, P < .001).
The severity did not correlate to Ves v 1 or the size of the skin prick
test reaction wheal.
Serum basal tryptase level was increased (>13 μg/L) in 8 pa-
tients whose tryptase level ranged from 26 to 257 μg/L. Of these
patients, 5 (62–75 years old) had mastocytosis and the KIT D816V
mutation in bone marrow cells. Of these 5 patients, 4 were diag-
nosed after the allergic reaction to YJV and serum basal tryptase
measurement.
Table 1
Baseline Characteristics and Results of Diagnostic Tests of the 78 Patients With Suspected Yellowjacket Venom Allergy
Non-SAR (n = 31) SAR (n = 47) P valuea
Age (y), mean (SD) 39 (5–72) 47 (1–75) .702
Men, n (%) 7 (22) 22 (47) .034
Time from sting to blood sampling (mo) 18 (0–175) 3 (0–387) .007
Asthma, n (%) 12 (41) 11 (23) .098
Other allergy, n (%) 19/31 (61) 7 (15) .000
Objective symptoms, n (%)
Large local reaction 23 (74) 21 (45) .010
Hypotension 0 13 (28) .001
Loss of consciousness 0 10 (23) .011
Vomiting or diarrhea 0 11/44 (25) .005
Airway obstruction 0 7/44 (16) .043
Angioedema 0 18 (38) .000
Urticaria 0 28 (60) .000
Anaphylactic shock 0 9 (19) .010
Subjective symptoms, n (%)
Tightness of chest 14/25 (56) 18/44 (41) .227
Dizziness 9/25 (36) 19/44 (43) .617
Treatment of latest reaction, n (%)
Received glucocorticoids 11 (28) 28 (72) .037
Received epinephrine 4 (13) 24 (51) .001
Received rescue fluid therapy 0 12 (86) .002
Emergency department visit 14/30 (48%) 37 (79) .006
Serum sIgE
sYJV (kU/L), median (range) 0.08 (0.01–100) 2.76 (0.01–100) .000
Honeybee venom (kU/L), median (range) 0.04 (0.01–3.88) 0.05 (0.03–36.9) .031
Ves v 1 (kU/L), median (range) 0.01 (0–100) 0.02 (0.01–19.7) .108
Ves v 5 (kU/L), median (range) 0.07 (0–96.7) 3.48 (0.01–100) .000
Api m 1 (kU/L), median (range) 0.01 (0–0.11) 0.01 (0–0.48) .850
CCD (kU/L), median (range) 0.01 (0–2.49) 0.01 (0–3.09) .92
sYJV > 0.35 kU/L, n (%) 8 (26) 41/46 (89) .000
Honeybee venom > 0.35 kU/L, n (%) 2/29 (7) 9/46 (20) .186
Ves v 1 > 0.35 kU/L, n (%) 2 (7) 5/45 (11) .694
Ves v 5 > 0.35 kU/L, n (%) 10 (32) 39/46 (85) .000
Api m 1 > 0.35 kU/L, n (%) 0 1/46 (2) 1.00
Double sensitization to sYJV and honeybee whole venom extracts, n (%) 2/28 (7) 9/46 (20) .190
CCD > 0.35 kU/L, n (%) 2/23 (9) 4/40 (10) 1.00
Tryptase (μg/L), median (range) 4.63 (1.10–257) 3.9 (1.40–75.8) .191
Tryptase > 13 μg/L, n (%) 3/30 (10) 5/46 (11) 1.00
Skin prick test (titrated) reaction wheal ≥ 3 mm, n (%)
YJV 11/24 (46) 30/35 (86) .002
Honeybee venom 12/24 (50) 17/34 (50) 1.00
Double sensitization 7/24 (29) 16/34 (47) .188
Positive immunoblot test reaction, n (%)
YJV 8/30 (27) 28/45 (62) .004
Honeybee venom 0 4/44 (9) .147
Started venom immunotherapy 5 (18) 23 (55) .012
Abbreviations: CCD, cross-reactive carbohydrate determinant; SAR, systemic allergic reaction; sIgE, specific immunoglobulin E; sYJV, spiked yellowjacket venom; YJV, yellowjacket
venom.
aP values were determined using Pearson χ2, Fisher exact, or Mann-Whitney U test.
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Discussion
Specific IgE to the yellowjacket whole-venom extract that was
spiked with Ves v 5 (sYJV) was superior to other in vitro tests or
puncture skin tests in confirming venom sensitization after a SAR.
In agreement with previous studies, specific IgE to Ves v 5 per-
formed well, but Ves v 1 added no value. Despite the 86% sensitivity
of skin prick tests, their usefulness was inferior because of the low
specificity and large number of double-positive test results to YJV
and honeybee venom. The in-house immunoblot test was inferior
to serum-specific IgE or skin prick tests.
Measuring specific IgE to the venom allergen components instead
of whole-venom extracts has improved the diagnosis of YJV allergy.16
Spiking the yellowjacket whole-venom IgE test with Ves v 5 since
2012 has improved its sensitivity.12 In our study, 47% of samples
that were negative in the conventional non-sYJV–specific IgE test
were positive in the test spiked with Ves v 5. Spiking explains the
good correlation (r = 0.98) between these 2 tests.12 Sensitivity of
the sYJV was higher (89%) than that of Ves v 5 alone (85%), but the
combination of these 2 tests yielded 90% sensitivity. Measuring IgE
to the whole-venom extract seems to be useful, because the venom
could contain other relevant allergen components.17
Unexpectedly, measuring IgE to Ves v 1 added no value in our
patients with SAR. Previously, sensitization to Ves v 1 was found
in 30% to 50% of patients with yellowjacket allergy,14,16,17 but mono-
sensitization has been rare.
The weakness of our study is the lack of intradermal testing. In-
tradermal tests have been highly sensitive and they are
recommended as the first-line test in US guidelines.5 The sensitiv-
ity of skin prick tests is lower than of intradermal tests (86%), and
their usefulness is limited by the frequent double sensitization to
yellowjacket and honeybee venoms. Skin prick tests also fre-
quently indicate positivity in patients without a SAR.
Double positivity to the 2 venoms could indicate true double sen-
sitization or could be caused by cross-sensitization. Previously, 50%
to 60% double positivity has been reported in serum tests.18 To our
knowledge, little evidence exists on the performance and double
positivity of skin prick tests compared with serum-specific IgE tests
including recombinant allergen components. Previously, double posi-
tivity has been more common in conventional serum IgE tests than
Figure 1. Receiver-operating characteristics (ROC) curve showing the performance of the diagnostic tests for yellowjacket allergy. IgE, immunoglobulin E.
Table 2
Performance of Diagnostic Tests in Patients With a Systemic Allergic Reaction (n = 47) and With a Large Local or Other Reaction (n = 31) to a Yellowjacket Sting
Positive diagnostic test Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%) Likelihood ratio
sIgE > 0.35 kU/L in ImmunoCAP
sYJVa 89 (76–96) 74 (55–88) 84 (74–90) 82 (66–92) 3.4 (1.9–6.3)
Ves v 5 85 (71–94) 68 (48–83) 80 (70–87) 75 (59–86) 2.6 (1.6–4.4)
Ves v 1 11 (4–24) 94 (78–99) 71 (34–92) 42 (39–45) 1.7 (0.4–8.3)
sYJVa or Ves v 5 90 (78–97) 61 (42–78) 79 (71–86) 79 (61–90) 2.3 (1.5–3.7)
Immunoblot 62 (46–76) 73 (54–88) 78 (61–90) 56 (40–72) 2.3 (1.2–4.4)
Skin prick test reaction wheal > 3 mm
Titratedb 86 (70–95) 54 (33–74) 73 (63–81) 72 (51–86) 1.9 (1.2–2.9)
100 μgc 58 (41–75) 62 (41–81) 69 (55–80) 51 (39–64) 1.6 (0.9–2.8)
300 μgd 84 (66–94) 59 (36–79) 74 (63–83) 72 (52–86) 2.0 (1.2–3.5)
Abbreviations: sIgE, specific immunoglobulin E; sYJV, spiked yellowjacket venom.
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in skin prick tests,19 but regional differences can occur in the sen-
sitization profiles of patients with insect venom allergy.20 In our study
using the sYJV, double positivity to YJV and honeybee venom was
much more common in skin prick tests than in serum tests. In agree-
ment with previous studies, double sensitization was mainly
independent of CCD sensitization.21
In this population with suspected venom allergy, sensitization
to sYJV was frequent in patients without a SAR but with a large local
reaction, and the specificity of the tests was not optimal. This could
be due to the fact that up to 80% of patients with a large local re-
action are sensitized to venom IgE. Up to 46% of patients without
a SAR were sensitized in the titrated skin prick tests, and 26% were
sensitized in conventional serum tests. Although all patients were
referred for suspected venom allergy, the thorough history did not
always confirm a SAR. Therefore, before screening for venom sen-
sitization, the history of SAR should be confirmed. The prevalence
of sensitization to Hymenoptera venoms is estimated to be 10% to
40% in the general population.11 Sensitized individuals have an in-
creased risk of having a large local reaction to a sting, but the risk
for a SAR in sensitized asymptomatic patients is lower than 6%.11
The 5% of our patients who had serum basal tryptase level higher
than 20 μg/L were newly diagnosed with systemic mastocytosis and
the KIT D816V mutation and fulfilled the World Health Organiza-
tion minor diagnostic criterion. An anaphylactic reaction to
Hymenoptera sting could be an indicator of indolent mastocyto-
sis; therefore, it is useful to measure serum basal tryptase after a
SAR to Hymenoptera stings.4,22,23
The small number of patients with a SAR to honeybee sting and
the lack of commercial tests to Api m 10 and Api m 4 during the
study did not allow us to evaluate the performance of the serum
tests in honeybee allergy.
The wide interval from the latest sting to blood sampling could
affect the results; after an initial decrease (hours), venom-specific
IgE increases up to 5-fold from 1 to 4 weeks after the sting and then
gradually decreases.11 The results did not change after adjusting for
the time interval.
In conclusion, use of a venom-specific IgE measurement should
be reserved for patients with a verified SAR who would be consid-
ered for VIT. For this indication, in patients with suspected YJV
allergy, when intradermal venom skin tests are not performed, the
diagnostic tests of choice are serum-specific IgE to sYJV and Ves v
5. Using venom allergen component-specific IgE tests could improve
the diagnosis of IgE-mediated YJV allergy, a prerequisite for VIT after
a SAR. An in-house immunoblot added no value and should not be
used in selecting patients for VIT, because even if the result is pos-
itive, the VIT extract might not contain the specific allergens. VIT
in patients who are not sensitized to the culprit allergens carries
risks and might not be efficient.10
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